Karyopharm Therapeutics
Karyopharm reduces employees by 20% as Xpovio sales for blood cancer remain stagnant
SG Tylor
Source – Karyopharm Therapeutics Karyopharm Therapeutics, faced with stagnant sales of its only approved product, Xpovio (selinexor), has announced a ...
SELINEXOR AND RUXOLITINIB’S PHASE III TRIAL IN JAKI-NAIVE MYELOFIBROSIS BEGINS
SG Tylor
Source – Karyopharm Therapeutics Karyopharm Therapeutics has initiated a Phase III clinical trial (NCT04562389) to evaluate the effectiveness and safety ...
